Mesylate

This page contains recent news articles, when available, and an overview of Mesylate but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Mesylate (when available)

Pharmacology and use:
Troglitazone is an oral antihyperglycemic agent which acts primarily by decreasing insulin resistance. Troglitazone is used in the management of type II diabetes (noninsulin-dependent diabetes mellitus (NIDDM) also known as adult-onset diabetes). It improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis. Troglitazone is not chemically or functionally related to either the sulfonylureas, the biguanides, or the g-glucosidase inhibitors. Troglitazone may be used concomitantly with a sulfonylurea or insulin to improve glycemic control. For the treatment of Type II diabetes mellitus

Mechanism Of Action:
Troglitazone is a thiazolidinedione antidiabetic agent that lowers blood glucose by improving target cell response to insulin. It has a unique mechanism of action that is dependent on the presence of insulin for activity. Troglitazone decreases hepatic glucose output and increases insulindependent glucose disposal in skeletal muscle. Its mechanism of action is thought to involve binding to nuclear receptors (PPAR) that regulate the transcription of a number of insulin responsive genes critical for the control of glucose and lipid metabolism. Unlike sulfonylureas, troglitazone is not an insulin secretagogue.

News Articles on Troglitazone

Eribulin Mesylate Demonstrated Anti-Tumor Activity In Patients ...  -  02 Jun 2008
The investigational chemotherapeutic agent eribulin mesylate (E7389) demonstrated activity in a heavily pretreated population of women with locally advanced Medical News Today (press release),

Rethinking section 3(d) in light of the Novartis judgment  -  02 Jun 2008
Claims in the patent applications show that the patent is granted not on the compound in its free state but also for the salt form of Imatinib mesylate. Indlaw.com,

ChemGenex Investigators Present Data on Clinical Activity of ...  -  02 Jun 2008
...in patients who have failed to respond to the tyrosine kinase inhibitor imatinib mesylate (Gleevec(R)) the current, standard front-line treatment. Centre Daily Times,

US Oncology Affiliated Physicians Make a Strong Showing in ASCO ...  -  02 Jun 2008
MD, Ph.D., Texas Oncology-Baylor Charles A Sammons Cancer Center: Phase II study of eribulin mesylate in patients with locally advanced or metastatic Earthtimes (press release),

ChemGenex Investigators Present Data on Clinical Activity of ...  -  02 Jun 2008
...in patients who have failed to respond to the tyrosine kinase inhibitor imatinib mesylate (Gleevec ® ) the current, standard front-line treatment. Ad-Hoc-News (Pressemitteilung),

Market Report -- In Play (CXSP)  -  02 Jun 2008
...in patients who have failed to respond to the tyrosine kinase inhibitor imatinib mesylate (Gleevec) the current, standard front-line treatment. MSN Money

Combination Of Two Novel Anti-cancer Agents May Help Fight CML ...  -  May 29, 2008
Imatinib mesylate, or Gleevec, is a highly effective anti-cancer agent that has revolutionized the course of therapy for patients with CML. Science Daily (press release)

Eisai says drug active in advanced breast cancer  -  May 15, 2008
TOKYO (Reuters) - Japan's Eisai Co Ltd (4523.T: Quote, Profile, Research) said on Friday that its experimental treatment for advanced breast cancer had Reuters

OraVerse approved for dental anesthetic recovery  -  May 12, 2008
Novalar has received approval to market OraVerse (phentolamine mesylate injection) for the reversal of soft-tissue anesthesia and the associated functional Prescribing Reference,

Oscient Pharmaceuticals Reports First Quarter 2008 Financial Results  -  May 7, 2008
...$12.6 million in revenue from the cardiovascular drug ANTARA and $5.8 million in revenue from the antibiotic FACTIVE(R) (gemifloxacin mesylate) tablets. FOXBusiness

Eisai's Commitment to Oncology Demonstrated by Clinical Data to be ...  -  May 15, 2008
...and Ovarian Cancer A1 Poster 27C Eribulin Phase II Study of Eribulin June 2, 2008 Mesylate (E7389) Mesylate (E7389) in Patients 2:00-6:00 pm Abstract PR Newswire (press release),

Noven Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript  -  May 30, 2008
Mesafem, as you know, is a low-dose paroxetine mesylate product that we're developing for moderate to severe vasomotor systems associated with menopause. Seeking Alpha,

Protein Predicts Gleevec Resistance In Gastrointestinal Tumors  -  May 15, 2008
...to the drug imatinib mesylate (known as Gleevec), according to Andrew K. Godwin, Ph.D., a researcher at the Fox Chase Cancer Center in Philadelphia. Science Daily (press release)

Dental anesthesia reversal drug OK'd  -  May 10, 2008
Weber and Katz patented phentolamine mesylate for dental anesthesia reversal. And in 2001, Weber founded Novalar to take the product to market. San Diego Union Tribune,

Gastrointestinal Stromal Tumor Metastatic to the Scrotum  -  May 22, 2008
2 The patient was considered inoperable and received medical therapy with imatinib mesylate. Figure 4. Specimen obtained by sonographically guided needle Journal of Ultrasound in Medicine (subscription)

A 60-Year-Old Woman in Chronic Phase Chronic Myeloid Leukemia (CML ...  -  May 20, 2008
Disclosure: Sources of funding for research: Bristol-Myers Squibb, Novartis. Speakers' bureau/honorarium agreements: Bristol-Myers Squibb, Medscape (subscription)

New Pfizer Data in Lung Cancer, Ewing's Sarcoma, Prostate Cancer ...  -  May 16, 2008
...of advanced renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. Earthtimes (press release),

Novartis's Ranjit Shahani: Patenting Innovation 'Is the Best ...  -  May 15, 2008
Furthermore, generic-makers in India have yet to come forward with an access program for generic imatinib mesylate [Glivec's generic name]. Knowledge@Wharton (subscription),

Benda Pharmaceutical Jiangling Plant Awarded GMP Certificate For  -  May 13, 2008
Jiangling Benda plans to produce four types of Active Pharmaceutical Ingredients (APIs), including Ribavrin, Asarin, Levofloxacin Mesylate and Ribose. Pharmaceutical Online (press release),

Benda Pharmaceutical Jiangling Plant Awarded GMP Certificate for ...  -  May 13, 2008
Jiangling Benda plans to produce four types of Active Pharmaceutical Ingredients (APIs), including Ribavrin, Asarin, Levofloxacin Mesylate and Ribose. PR Newswire (press release),

ALSO NOTED: FDA OKs Novalar therapy; StemCells files new patent ...  -  May 12, 2008
The FDA has OK'd Novalar's OraVerse (phentolamine mesylate) for the reversal of soft-tissue anesthesia and the associated functional deficits resulting from FierceBiotech,

OSCI: CEO Discusses Q1 Results; Sees Revenue Growth from ANTARA(R)  -  May 7, 2008
FACTIVE(R) (gemifloxacin mesylate), a fluoroquinolone antibiotic is approved for the treatment of acute bacterial exacerbations of chronic bronchitis and Trading Markets (press release),

US intervenes in Pfizer trial  -  Apr 21, 2008
Plaintiff was disturbed that , Pfizer “ did create , experiment and brought to the market its product, Trovafloxacin Mesylate “ which it branded “Trovan�? Business Day,

AACR Roundup  -  Apr 15, 2008
Another presentation showed that the tyrosine kinase inhibitor imatinib mesylate did not reduce leukemic stem cell number, and it caused a rapid and TMCnet

Therapy Puts Melanoma Into Remission  -  Apr 20, 2008
Because the tumor cells had an abnormality in a gene called KIT, the patient enrolled in a study of Gleevec (imatinib mesylate) -- a drug known to target Ivanhoe,

Noven Announces 2007 Financial Results  -  Mar 27, 2008
Oral products currently offered through the Noven marketing and sales infrastructure consist of Pexeva(R) (paroxetine mesylate) and Lithobid(R) (lithium FOXBusiness

Update in the Management of Gastrointestinal Stromal Tumors (GIST ...  -  Mar 31, 2008
Masatinib mesylate was tested in the front-line setting in patients with metastatic and unresectable disease.[17] This agent has been shown to have greater Cancer Consultants,

Six years survival on imatinib with no disease progression after ...  -  Apr 18, 2008
She was commenced on imatinib mesylate (Glivec) chemotherapy. This case report was prepared from the medical records and radiology reports. 7thSpace Interactive (press release),

Lilly Reports Solid First-Quarter Results  -  Apr 21, 2008
Lilly) Arxxant(TM) (ruboxistaurin mesylate, Lilly) Byetta(R) (exenatide injection, Amylin Pharmaceuticals) Cialis(R) (tadalafil, Lilly) Comfortis(TM) Earthtimes,

India pulling ahead of China on CT outsourcing, says Planning ...  -  Apr 17, 2008
...which followed the rejection of a controversial product patent application for Novartis’ anticancer Glivec (imatinib mesylate), prompted the company to Pharma Times (subscription),

BUYINS.NET: COMV, FRPT, MCHX, OSCI, STXS, TBSI Have Also Been On ...  -  Apr 11, 2008
...and FACTIVE (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic used for the treatment of acute bacterial exacerbations of chronic bronchitis Manufacturing Business Technology,

Pfizer to launch free Sutent access programme in Nepal  -  Apr 2, 2008
Natco had in January applied to the patent controller of India to allow the company to manufacture and export sunitinib mesylate (generic name of Sutent) to Livemint,

Notice to Readers: Updated Information Regarding Antiretroviral ...  -  Mar 25, 2008
New York, New York), another protease inhibitor, because the Viracept manufactured in Europe contained high levels of ethyl methane mesylate (EMS). Journal of American Medical Association (subscription),

Updates in the Management of Chronic Myeloid Leukemia (CML): A ...  -  Mar 31, 2008
Survival benefit with imatinib mesylate versus interferon alfa based regimens in newly diagnosed chronic phase chronic myelogenous leukemia. Blood. Cancer Consultants,

Oscient Pharmaceuticals Provides Preliminary Revenue Results for ...  -  Apr 16, 2008
The Company reiterates its previously announced guidance of $96-$103 million in revenues from ANTARA and FACTIVE(R) (gemifloxacin mesylate) tablets in 2008 PharmaLive.com (press release),

ChemGenex Reports Oral Bioavailability of Omacetaxine and Expands ...  -  Apr 14, 2008
Mcl-1 levels were not reduced in the short term by imatinib mesylate. (Abstract 2350). "Following the clinical update presented last week showing PR-Inside.com (Pressemitteilung),

Market Report -- In Play (CXSP)  -  Apr 14, 2008
Significantly, the tyrosine kinase inhibitor (TKI) imatinib mesylate did not reduce leukemic stem cell number. (Abstract 2275). Omacetaxine causes a rapid MSN Money

Streetinvesting.com: Progressive Following on Oscient ...  -  Apr 16, 2008
...in the United States: ANTARA (fenofibrate) capsules, a cardiovascular product and FACTIVE (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic. Trading Markets (press release),

Moderate Hypothermia as Treatment for Spinal Cord Injury  -  11 Mar 2008
Administration of methylprednisolone for 24 or 48 hours or trilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Ortho SuperSite,

Viracept Pulled From NIH Guidelines for Pediatric HIV Treatments  -  11 Mar 2008
Roche manufactures Viracept (nelfinavir mesylate) for markets in Europe, and Pfizer makes the drug for use in the US Pfizer sent “dear doctor�? letters last FDA news (subscription),

Actavis Extends Portfolio With Four New Products in the US  -  Feb 28, 2008
Benztropine mesylate is an antidrykinetic, which reduces the symptoms of Parkinson's disease by improving muscle control and reducing stiffness. FOXBusiness

Noven Announces 2007 Earnings Release Date  -  Mar 6, 2008
Oral products currently offered through Noven's psychiatry/CNS marketing and sales organization consist of Pexeva(R) (paroxetine mesylate) and Lithobid(R) Trading Markets (press release),

Pfizer Accuses FG of Delaying Proceedings  -  Feb 19, 2008
Government had filed the suit against the pharmacueitcal company after declaring that its administering of Trovaflozacin mesylate, popularly it branded AllAfrica.com,

Imatinib Effective Over Long Term in Refractory Leukemia  -  Feb 26, 2008
NEW YORK FEB 25, 2008 (Reuters Health) - Imatinib mesylate therapy shows lasting safety and efficacy in chronic-phase chronic myeloid leukemia (CML) Cancerpage.com,

Oscient Pharmaceuticals to Participate in the Roth Capital ...  -  Feb 14, 2008
...highlight details on the recent market performance of ANTARA(R) (fenofibrate) capsules and FACTIVE(R) (gemifloxacin mesylate) tablets in the US; Centre Daily Times,

Targeted Therapies: A New Generation of Cancer Treatments  -  Mar 6, 2008
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia [published correction appears in N Engl J Med. RedOrbit,

Greeks attend must give wait command pretty.  -  Mar 5, 2008
With coursers heavenly witness [url=http://cowdump.com/doxazosin-lipophilicity/]doxazosin mesylate[/url] his enemy Goniec Polski - Polski Magazyn w Wielkiej Brytanii,

BUYINS.NET: HDP, MEG, CTCT, GRIN, IFNY, OSCI Have Been Added To ...  -  Mar 4, 2008
...and FACTIVE (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic used for the treatment of acute bacterial exacerbations of chronic bronchitis Trading Markets (press release),

Novartis vaccines institute sets sights on developing world diseases  -  Feb 26, 2008
...challenge to India's Patents (Amendment) Act, 2005 over rights to a beta-crystal form of the company's anticancer Glivec (imatinib mesylate). In-PharmaTechnologist.com,

New Oral Oncology Drugs Bring Great Benefits but Challenges With ...  -  Feb 14, 2008
Gleevec (imatinib mesylate) and Sprycel (dasatinib). In their most recent drug trend reports, PBMs Express Scripts, Inc. and Medco Health Solutions, Atlantic Information Services, Inc.,

Meta-analysis: Effectiveness of Drugs for Preventing Contrast ...  -  Feb 18, 2008
Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA. 2003;290:2284-91. [PMID: 14600187]. Annals of Internal Medicine

Brand Names/Synonyms:
Mesylate is also known by the following brand names and/or synonymsRomglizone; Rezulin; Troglitazone [USAN:BAN:INN]; Prelay; Noscal; Mesylate

Drug Category:
Mesylate is categorized under the following by the FDA: Vasodilator Agents; Hypoglycemic Agents; Platelet Aggregation Inhibitors; Fibrinolytic Agents; Antineoplastic Agents; ATC:A10BG01

Dosage Forms:
Not Available

Absorption:
Absorbed rapidly. Food increases the extent of absorption by 30% to 85%.

Interactions:
Interactions for Troglitazone: Oral Contraceptives: Administration of Troglitazone with an oral contraceptive containing ethinyl estradiol and norethindrone reduced the plasma concentrations of both by approximately 30% which could result in loss of contraception. Therefore, a higher dose of oral contraceptive or an alternative method of contraception should be considered. Terfenadine: Coadministration of Troglitazone with terfenadine decreases the plasma concentration of both terfenadine and its active metabolite by 50-70% and may result in decreased efficacy of terfenadine. Cholestyramine: Concomitant administration of cholestyramine with Troglitazone reduces the absorption of troglitazone by 70%; thus, coadministration of cholestyramine and Troglitazone is not recommended. Glyburide: Coadministration of Troglitazone and glyburide does not appear to alter troglitazone or glyburide pharmacokinetics. Digoxin: Coadministratjon of Troglitazone with digoxin does not alter the steady-state pharmacokinetics of digoxin. Warfarin: Troglitazone has no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin therapy. Acetaminophen: Coadministration of acetaminophen and Troglitazone does not alter the pharmacokinetics of either drug. Metformin: No information is available on the use of Troglitazone with metformin. Ethanol: A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in Troglitazone-treated patients with type II diabetes mellitus. The above interactions with terfenadine and oral contraceptives suggest that troglitazone may induce drug metabolism by CYP3A4. Studies have not been performed with other drugs metabolized by this enzyme such as: astemizole, calcium channel blockers, cisapride, corticosteroids cyclosporine. HMG-CoA reductase inhibitors, tacrolimus, triazolam, and trimetrexate. The possi bility of altered safety and efficacy should be considered when Troglitazone is used concomitantly with these drugs. Patients stable on one or more of these agents when Troglitazone is started should be closely monitored and their therapy adjusted as necessary.

Chemical IUPAC Name:
5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-chroman-2-yl)methoxy]phenyl]methyl]thiazolidine-2,4-dione

:

Web health.mongabay.com

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.